Among the MYC family, MYCN is critical in NB progression and therapy resistance, and its higher expression is linked with poor prognosis and survival irrespective of the risk group in NB patients (Brodeur et al., 1984; Fredlund et al., 2008). This evidence concerns the gene MYCN and neuroblastoma.